Report overview
The global Measles, Mumps, and Rubella Vaccines market size is estimated to be $530 million in 2023, and MAResearch analysts predict it will reach $888 million by 2032, growing at a CAGR of 5.9% during the forecast period from 2024 to 2032.
This report studies the Measles, Mumps, and Rubella Vaccines market, covering market size for segment by type (Monovalent Vaccine, Polyvalent Vaccine, etc.), by application (Children, Adults, etc.), by sales channel (Direct Channel, Distribution Channel), by player (Medlmmune, Johnson & Johnson, Merck, Sanofi, GlaxoSmithKline, etc.) and by region (North America, Europe, Asia-Pacific, South America and Middle East & Africa).
This report provides detailed historical analysis of global market for Measles, Mumps, and Rubella Vaccines from 2018-2023, and provides extensive market forecasts from 2024-2032 by region/country and subsectors. It covers the sales/revenue/value, gross margin, historical growth and future perspectives in the Measles, Mumps, and Rubella Vaccines market.
Leading Players of Measles, Mumps, and Rubella Vaccines including:
Medlmmune
Johnson & Johnson
Merck
Sanofi
GlaxoSmithKline
Pfizer
CSL
Serum
Bavarian Nordic
Astellas Pharma
Emergent BioSolutions
Sinopharm
Market split by Type:
Monovalent Vaccine
Polyvalent Vaccine
Market split by Application:
Children
Adults
Market split by Sales Channel:
Direct Channel
Distribution Channel
Market split by Region/Country:
North America (United States and Canada)
Europe (Germany, UK, France, Italy, Spain, and Russia, etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, and Southeast Asia, etc.)
South America (Brazil, Mexico, and Argentina, etc.)
Middle East & Africa (Turkey, UAE, Saudi Arabia, and South Africa, etc.)
If you have any special requirements, please let us know and we can provide you the customized report as you want.
